Recombinant alpha 2 interferon in the treatment of chronic myeloproliferative disorders.
Bonaccorso
R
R
Chair of Hematology and Chair of Medical Pathology, Institute of Clinical Medicine, University of Palermo, Italy.
Teresi
M
M
Gebbia
V
V
Tambone Reyes
M
M
Tinnirello
D
D
Di Marco
P
P
Citarrella
P
P
Mansueto
S
S
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood / Q000188:drug therapy*; D010974:Platelet Aggregation / Q000187:drug effects; D055728:Primary Myelofibrosis / Q000188:drug therapy; D011994:Recombinant Proteins; D013920:Thrombocythemia, Essential / Q000188:drug therapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins